Eagle Pharmaceuticals, which develops and sells enhanced injectable versions of expiring patented drugs, raised $50 million by offering 3.4 million shares at $15, the midpoint of the range of $14 to $16. Eagle Pharmaceuticals plans to list on the NASDAQ under the symbol EGRX. Eagle Pharmaceuticals initially filed confidentially on 10/21/2013. Piper Jaffray and William Blair acted as joint bookrunners on the deal.
